High-Density Lipoproteins: Nature's Multifunctional Nanoparticles

ACS Nano

Volumn 10, Issue 3, 2016, Pages 3015-3041

  Kuai, Rui ^a   Li, Dan ^a   Chen, Y Eugene ^b   Moon, James J ^a   Schwendeman, Anna ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

apolipoprotein mimetic peptides; apolipoproteins; delivery; high density lipoproteins; imaging reagents; multifunctional nanoparticles; nucleic acids; peptides; proteins; small molecules

Indexed keywords

CARDIOVASCULAR SYSTEM; CHOLESTEROL; DRUG PRODUCTS; LIPIDS; LIPOPROTEINS; LIPOSOMES; MOLECULES; NANOPARTICLES; NUCLEIC ACIDS; PEPTIDES; PHOSPHOLIPIDS; RECOMBINANT PROTEINS; RNA;

APOLIPOPROTEINS; DELIVERY; HIGH DENSITY LIPOPROTEIN; MULTI-FUNCTIONAL NANOPARTICLES; SMALL MOLECULES;

PROTEINS;

APOA1 PROTEIN, HUMAN; APOLIPOPROTEIN A1; DRUG CARRIER; HIGH DENSITY LIPOPROTEIN; NANOPARTICLE; RECOMBINANT PROTEIN;

ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; NANOMEDICINE; PROCEDURES;

ANIMALS; APOLIPOPROTEIN A-I; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOPROTEINS, HDL; NANOMEDICINE; NANOPARTICLES; RECOMBINANT PROTEINS;

EID: 84961967585     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/acsnano.5b07522     Document Type: Article

References (224)

1. Kingwell, B. A.; Chapman, M. J.; Kontush, A.; Miller, N. E. HDL-Targeted Therapies: Progress, Failures and Future Nat. Rev. Drug Discovery 2014, 13, 445-64 10.1038/nrd4279
2. Barr, D. P.; Russ, E. M.; Eder, H. A. Protein-Lipid Relationships in Human Plasma. II. In Atherosclerosis and Related Conditions Am. J. Med. 1951, 11, 480-93 10.1016/0002-9343(51)90183-0
3. Gofman, J. W. Serum Lipoproteins and The Evaluation of Atherosclerosis Ann. N. Y. Acad. Sci. 1956, 64, 590-5 10.1111/j.1749-6632.1956.tb36833.x
4. Wang, M.; Briggs, M. R. HDL: The Metabolism, Function, and Therapeutic Importance Chem. Rev. 2004, 104, 119-37 10.1021/cr020466v
5. Movva, R.; Rader, D. J. Laboratory Assessment of HDL Heterogeneity and Function Clin. Chem. 2008, 54, 788-800 10.1373/clinchem.2007.101923
6. Damiano, M. G.; Mutharasan, R. K.; Tripathy, S.; McMahon, K. M.; Thaxton, C. S. Templated High Density Lipoprotein Nanoparticles as Potential Therapies and for Molecular Delivery Adv. Drug Delivery Rev. 2013, 65, 649-62 10.1016/j.addr.2012.07.013
7. Nofer, J. R.; Kehrel, B.; Fobker, M.; Levkau, B.; Assmann, G.; von Eckardstein, A. HDL and Arteriosclerosis: Beyond Reverse Cholesterol Transport Atherosclerosis 2002, 161, 1-16 10.1016/S0021-9150(01)00651-7
8. Vance, D. E.; Vance, J. E. Biochemistry of Lipids, Lipoproteins and Membranes, 5th ed.; Elsevier B.V., 2008.
9. Kontush, A.; Chapman, M. J. Antiatherogenic Function of HDL Particle Subpopulations: Focus on Antioxidative Activities Curr. Opin. Lipidol. 2010, 21, 312-8 10.1097/MOL.0b013e32833bcdc1
10. Vickers, K. C.; Palmisano, B. T.; Shoucri, B. M.; Shamburek, R. D.; Remaley, A. T. MicroRNAs are Transported in Plasma and Delivered to Recipient Cells by High-Density Lipoproteins Nat. Cell Biol. 2011, 13, 423-33 10.1038/ncb2210
11. Khan, M. L. N.; Drake, S. L.; Crockatt, J. G.; Dasseux, J. L. H. Single-Dose Intravenous Infusion of ETC-642, a 22-mer ApoA-I Analogue and Phospholipids Complex, Elevates HDL-C in Atherosclerosis Patients Circulation 2003, 108, 563-564
12. Navab, M.; Anantharamaiah, G. M.; Reddy, S. T.; Van Lenten, B. J.; Datta, G.; Garber, D.; Fogelman, A. M. Human Apolipoprotein A-I and A-I Mimetic Peptides: Potential for Atherosclerosis Reversal Curr. Opin. Lipidol. 2004, 15, 645-9 10.1097/00041433-200412000-00004
13. Navab, M.; Reddy, S. T.; Van Lenten, B. J.; Fogelman, A. M. HDL and Cardiovascular Disease: Atherogenic and Atheroprotective Mechanisms Nat. Rev. Cardiol. 2011, 8, 222-32 10.1038/nrcardio.2010.222
14. Tuteja, S.; Rader, D. J. High-Density Lipoproteins in the Prevention of Cardiovascular Disease: Changing the Paradigm Clin. Pharmacol. Ther. 2014, 96, 48-56 10.1038/clpt.2014.79
15. Cho, W. S.; Cho, M. J.; Jeong, J.; Choi, M.; Cho, H. Y.; Han, B. S.; Kim, S. H.; Kim, H. O.; Lim, Y. T.; Chung, B. H.; Jeong, J. Acute Toxicity and Pharmacokinetics of 13 nm-Sized PEG-Coated Gold Nanoparticles Toxicol. Appl. Pharmacol. 2009, 236, 16-24 10.1016/j.taap.2008.12.023
16. Khlebtsov, N.; Dykman, L. Biodistribution and Toxicity of Engineered Gold Nanoparticles: A Review of in Vitro and in Vivo Studies Chem. Soc. Rev. 2011, 40, 1647-1671 10.1039/C0CS00018C
17. Krause, B. R.; Remaley, A. T. Reconstituted HDL for the Acute Treatment of Acute Coronary Syndrome Curr. Opin. Lipidol. 2013, 24, 480-6 10.1097/MOL.0000000000000020
18. Nanjee, M. N.; Doran, J. E.; Lerch, P. G.; Miller, N. E. Acute Effects of Intravenous Infusion of ApoA1/Phosphatidylcholine Discs on Plasma Lipoproteins in Humans Arterioscler., Thromb., Vasc. Biol. 1999, 19, 979-89 10.1161/01.ATV.19.4.979
19. Lerch, P. G.; Fortsch, V.; Hodler, G.; Bolli, R. Production and Characterization of a Reconstituted High Density Lipoprotein for Therapeutic Applications Vox Sang. 1996, 71, 155-64 10.1046/j.1423-0410.1996.7130155.x
20. Spieker, L. E.; Sudano, I.; Hurlimann, D.; Lerch, P. G.; Lang, M. G.; Binggeli, C.; Corti, R.; Ruschitzka, F.; Luscher, T. F.; Noll, G. High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men Circulation 2002, 105, 1399-402 10.1161/01.CIR.0000013424.28206.8F
21. Bisoendial, R. J.; Hovingh, G. K.; Levels, J. H.; Lerch, P. G.; Andresen, I.; Hayden, M. R.; Kastelein, J. J.; Stroes, E. S. Restoration of Endothelial Function by Increasing High-Density Lipoprotein in Subjects with Isolated Low High-Density Lipoprotein Circulation 2003, 107, 2944-8 10.1161/01.CIR.0000070934.69310.1A
22. van Oostrom, O.; Nieuwdorp, M.; Westerweel, P. E.; Hoefer, I. E.; Basser, R.; Stroes, E. S.; Verhaar, M. C. Reconstituted HDL Increases Circulating Endothelial Progenitor Cells in Patients with Type 2 Diabetes Arterioscler., Thromb., Vasc. Biol. 2007, 27, 1864-5 10.1161/ATVBAHA.107.143875
23. Shaw, J. A.; Bobik, A.; Murphy, A.; Kanellakis, P.; Blombery, P.; Mukhamedova, N.; Woollard, K.; Lyon, S.; Sviridov, D.; Dart, A. M. Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque Circ. Res. 2008, 103, 1084-91 10.1161/CIRCRESAHA.108.182063
24. Patel, S.; Drew, B. G.; Nakhla, S.; Duffy, S. J.; Murphy, A. J.; Barter, P. J.; Rye, K. A.; Chin-Dusting, J.; Hoang, A.; Sviridov, D.; Celermajer, D. S.; Kingwell, B. A. Reconstituted High-Density Lipoprotein Increases Plasma High-Density Lipoprotein Anti-Inflammatory Properties and Cholesterol Efflux Capacity in Patients with Type 2 Diabetes J. Am. Coll. Cardiol. 2009, 53, 962-71 10.1016/j.jacc.2008.12.008
25. Calkin, A. C.; Drew, B. G.; Ono, A.; Duffy, S. J.; Gordon, M. V.; Schoenwaelder, S. M.; Sviridov, D.; Cooper, M. E.; Kingwell, B. A.; Jackson, S. P. Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals with Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux Circulation 2009, 120, 2095-104 10.1161/CIRCULATIONAHA.109.870709
26. Tardif, J. C.; Gregoire, J.; L'Allier, P. L.; Ibrahim, R.; Lesperance, J.; Heinonen, T. M.; Kouz, S.; Berry, C.; Basser, R.; Lavoie, M. A.; Guertin, M. C.; Rodes-Cabau, J. ects of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis: a Randomized Controlled Trial JAMA 2007, 297, 1675-82 10.1001/jama.297.15.jpc70004
27. Gille, A.; Easton, R.; D'Andrea, D.; Wright, S. D.; Shear, C. L. CSL112 Enhances Biomarkers of Reverse Cholesterol Transport After Single and Multiple Infusions in Healthy Subjects Arterioscler., Thromb., Vasc. Biol. 2014, 34, 2106-14 10.1161/ATVBAHA.114.303720
28. Easton, R.; Gille, A.; D'Andrea, D.; Davis, R.; Wright, S. D.; Shear, C. A Multiple Ascending Dose Study of CSL112, an Infused Formulation of ApoA-I J. Clin. Pharmacol. 2014, 54, 301-10 10.1002/jcph.194
29. A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers. https://clinicaltrials.gov/ct2/show/NCT01281774?term=CSL112&rank=3.
30. A Single Ascending Dose Study Examining The Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients. https://clinicaltrials.gov/ct2/show/NCT01499420?term=CSL112&rank=5.
31. A Phase 2b Study of CSL112 in Subjects with Acute Myocardial Infarction. https://clinicaltrials.gov/ct2/show/NCT02108262?term=CSL-112&rank=1.
32. Carlson, L. A. Effect of a Single Infusion of Recombinant Human Proapolipoprotein a-I Liposomes (Synthetic HDL) on Plasma-Lipoproteins in Patients with Low High-Density-Lipoprotein Cholesterol Nutr. Metab. Cardiovasc. Dis. 1995, 5, 85-91
33. Eriksson, M.; Carlson, L. A.; Miettinen, T. A.; Angelin, B. Stimulation of Fecal Steroid Excretion After Infusion of Recombinant Proapolipoprotein A-I-Potential Reverse Cholesterol Transport in Humans Circulation 1999, 100, 594-598 10.1161/01.CIR.100.6.594
34. Bisgaier, C. L.; Rodriguez, W. V.; Lalwani, N. D.; Hartman, D.; Johansson, J. Pharmaceutical Formulations, Methods and Dosing Regimens for the Treatment and Prevention of Acute Coronary Syndromes. Patent Appl. CA2542726 C, 2012.
35. Nissen, S. E.; Tsunoda, T.; Tuzcu, E. M.; Schoenhagen, P.; Cooper, C. J.; Yasin, M.; Eaton, G. M.; Lauer, M. A.; Sheldon, W. S.; Grines, C. L.; Halpern, S.; Crowe, T.; Blankenship, J. C.; Kerensky, R. Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients with Acute Coronary Syndromes: a Randomized Controlled Trial JAMA 2003, 290, 2292-300 10.1001/jama.290.17.2292
36. Dasseux, J.-L.; Oniciu, D. C.; Ackermann, R. Lipoprotein Complexes and Manufacturing and Uses Thereof. Patent Appl. US 20120232005 A1, 2012.
37. Keyserling, C. H.; Hunt, T. L.; Klepp, H. M.; Scott, R. A.; Barbaras, R.; Schwendeman, A.; Lalwani, N.; Dasseux, J. L. CER-001, a Synthetic HDL-Mimetic, Safely Mobilizes Cholesterol in Healthy Dyslipidemic Volunteers Circulation 2011, 124
38. Tardif, J. C.; Ballantyne, C. M.; Barter, P.; Dasseux, J. L.; Fayad, Z. A.; Guertin, M. C.; Kastelein, J. J. P.; Keyserling, C.; Klepp, H.; Koenig, W.; L'Allier, P. L.; Lesperance, J.; Luscher, T. F.; Paolini, J. F.; Tawakol, A.; Waters, D. D. Effects of the High-Density Lipoprotein Mimetic Agent CER-001 on Coronary Atherosclerosis in Patients with Acute Coronary Syndromes: a Randomized Trial Eur. Heart J. 2014, 35, 3277-3286 10.1093/eurheartj/ehu171
39. Hovingh, G. K.; Smits, L. P.; Stefanutti, C.; Soran, H.; Kwok, S.; de Graaf, J.; Gaudet, D.; Keyserling, C. H.; Klepp, H.; Frick, J.; Paolini, J. F.; Dasseux, J. L.; Kastelein, J. J. P.; Stroes, E. S. The Effect of an Apolipoprotein A-I-Containing High-Density Lipoprotein-Mimetic Particle (CER-001) on Carotid Artery Wall Thickness in Patients with Homozygous Familial Hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) Study Am. Heart J. 2015, 169, 736-U196 10.1016/j.ahj.2015.01.008
40. Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE). https://clinicaltrials.gov/ct2/show/NCT01412034?term=CER001&rank=1.
41. Exploratory Study of Plaque Regression (EXPRESS). https://clinicaltrials.gov/ct2/show/NCT01515241?term=CER001&rank=3.
42. Di Bartolo, B. A.; Nicholls, S. J.; Bao, S.; Rye, K. A.; Heather, A. K.; Barter, P. J.; Bursill, C. The Apolipoprotein A-I Mimetic Peptide ETC-642 Exhibits Anti-Inflammatory Properties That Are Comparable to High Density Lipoproteins Atherosclerosis 2011, 217, 395-400 10.1016/j.atherosclerosis.2011.04.001
43. Miles, J.; Khan, M.; Painchaud, C.; Lalwani, N.; Drake, S.; Dasseux, J. L. Single-Dose Tolerability, Pharmacokinetics, and Cholesterol Mobilization in HDL-C Fraction Following Intravenous Administration of ETC-642, a 22-mer ApoA-I Analogue and Phospholipids Complex, in Atherosclerosis Patients Proc. Arterioscl. Thromb. Vasc. Biol. 2004, 24, E19-E19
44. Esperion Begins Multiple-Dose Study of ETC-642 (RLT Peptide) In Patients with Stable Atherosclerosis. http://www.prnewswire.com/news-releases/esperion-begins-multiple-dose-study-of-etc-642-rlt-peptide-in-patients-with-stable-atherosclerosis-71438847.html.
45. Moguilevsky, N.; Varsalona, F.; Guillaume, J. P.; Gilles, P.; Bollen, A.; Roobol, K. Production of Authentic Human Proapolipoprotein-a-I in Escherichia-Coli-Strategies for the Removal of the Amino-Terminal Methionine J. Biotechnol. 1993, 27, 159-172 10.1016/0168-1656(93)90105-V
46. Kempen, H. J.; Schranz, D. B.; Asztalos, B. F.; Otvos, J.; Jeyarajah, E.; Drazul-Schrader, D.; Collins, H. L.; Adelman, S. J.; Wijngaard, P. L. Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size J. Lipids 2014, 2014, 923903 10.1155/2014/923903
47. Davidson, W.; Silva, R.; Chantepie, S.; Lagor, W.; Chapman, M.; Kontush, A. Proteomic Analysis of Defined Hdl Subpopulations Reveals Particle-Specific Protein Clusters: Relevance to Antioxidative Function Arterioscler., Thromb., Vasc. Biol. 2009, 29, 870 10.1161/ATVBAHA.109.186031
48. Bricarello, D. A.; Smilowitz, J. T.; Zivkovic, A. M.; German, J. B.; Parikh, A. N. Reconstituted Lipoprotein: A Versatile Class of Biologically-Inspired Nanostructures ACS Nano 2011, 5, 42-57 10.1021/nn103098m
49. Park, W.; Na, K. Advances in the Synthesis and Application of Nanoparticles for Drug Delivery Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2015, 7, 494-508 10.1002/wnan.1325
50. El-Sayed, I. H.; Huang, X. H.; El-Sayed, M. A. Selective Laser Photo-Thermal Therapy of Epithelial Carcinoma Using Anti-EGFR Antibody Conjugated Gold Nanoparticles Cancer Lett. 2006, 239, 129-135 10.1016/j.canlet.2005.07.035
51. Tkachenko, A. G.; Xie, H.; Coleman, D.; Glomm, W.; Ryan, J.; Anderson, M. F.; Franzen, S.; Feldheim, D. L. Multifunctional Gold Nanoparticle-Peptide Complexes for Nuclear Targeting J. Am. Chem. Soc. 2003, 125, 4700-4701 10.1021/ja0296935
52. Giljohann, D. A.; Seferos, D. S.; Prigodich, A. E.; Patel, P. C.; Mirkin, C. A. Gene Regulation with Polyvalent siRNA-Nanoparticle Conjugates J. Am. Chem. Soc. 2009, 131, 2072 10.1021/ja808719p
53. Wang, F.; Wang, Y. C.; Dou, S.; Xiong, M. H.; Sun, T. M.; Wang, J. Doxorubicin-Tethered Responsive Gold Nanoparticles Facilitate Intracellular Drug Delivery for Overcoming Multidrug Resistance in Cancer Cells ACS Nano 2011, 5, 3679-3692 10.1021/nn200007z
54. Rader, D. J. Molecular Regulation of HDL Metabolism and Function: Implications for Novel Therapies J. Clin. Invest. 2006, 116, 3090-3100 10.1172/JCI30163
55. Tall, A. R.; Yvan-Charvet, L.; Terasaka, N.; Pagler, T.; Wang, N. HDL, ABC Transporters, and Cholesterol Efflux: Implications for the Treatment of Atherosclerosis Cell Metab. 2008, 7, 365-375 10.1016/j.cmet.2008.03.001
56. Schwendeman, A.; Sviridov, D. O.; Yuan, W. M.; Guo, Y. H.; Morin, E. E.; Yuan, Y.; Stonik, J.; Freeman, L.; Ossoli, A.; Thacker, S.; Killion, S.; Pryor, M.; Chen, Y. E.; Turner, S.; Remaley, A. T. The Effect of Phospholipid Composition of Reconstituted HDL on Its Cholesterol Efflux and Anti-Inflammatory Properties J. Lipid Res. 2015, 56, 1727-1737 10.1194/jlr.M060285
57. Thaxton, C. S.; Daniel, W. L.; Giljohann, D. A.; Thomas, A. D.; Mirkin, C. A. Templated Spherical High Density Lipoprotein Nanoparticles J. Am. Chem. Soc. 2009, 131, 1384 10.1021/ja808856z
58. Cormode, D. P.; Skajaa, T.; van Schooneveld, M. M.; Koole, R.; Jarzyna, P.; Lobatto, M. E.; Calcagno, C.; Barazza, A.; Gordon, R. E.; Zanzonico, P.; Fisher, E. A.; Fayad, Z. A.; Mulder, W. J. M. Nanocrystal Core High-Density Lipoproteins: A Multimodality Contrast Agent Platform Nano Lett. 2008, 8, 3715-3723 10.1021/nl801958b
59. Luthi, A. J.; Zhang, H.; Kim, D.; Giljohann, D. A.; Mirkin, C. A.; Thaxton, C. S. Tailoring of Biomimetic High-Density Lipoprotein Nanostructures Changes Cholesterol Binding and Efflux ACS Nano 2012, 6, 276-285 10.1021/nn2035457
60. McMahon, K. M.; Mutharasan, R. K.; Tripathy, S.; Veliceasa, D.; Bobeica, M.; Shumaker, D. K.; Luthi, A. J.; Helfand, B. T.; Ardehali, H.; Mirkin, C. A.; Volpert, O.; Thaxton, C. S. Biomimetic High Density Lipoprotein Nanoparticles For Nucleic Acid Delivery Nano Lett. 2011, 11, 1208-1214 10.1021/nl1041947
61. Xie, J.; Xu, C.; Kohler, N.; Hou, Y.; Sun, S. Controlled PEGylation of Monodisperse Fe3O4 Nanoparticles for Reduced Non-Specific Uptake by Macrophage Cells Adv. Mater. 2007, 19, 3163 10.1002/adma.200701975
62. von Maltzahn, G.; Park, J. H.; Agrawal, A.; Bandaru, N. K.; Das, S. K.; Sailor, M. J.; Bhatia, S. N. Computationally Guided Photothermal Tumor Therapy Using Long-Circulating Gold Nanorod Antennas Cancer Res. 2009, 69, 3892-3900 10.1158/0008-5472.CAN-08-4242
63. Koole, R.; van Schooneveld, M. M.; Hilhorst, J.; Castermans, K.; Cormode, D. P.; Strijkers, G. J.; Donega, C. D.; Vanmaekelbergh, D.; Griffioen, A. W.; Nicolay, K.; Fayad, Z. A.; Meijerink, A.; Mulder, W. J. M. Paramagnetic Lipid-Coated Silica Nanoparticles with a Fluorescent Quantum Dot Core: A New Contrast Agent Platform for Multimodality Imaging Bioconjugate Chem. 2008, 19, 2471-2479 10.1021/bc800368x
64. Ishida, T.; Ichihara, M.; Wang, X.; Yamamoto, K.; Kimura, J.; Majima, E.; Kiwada, H. Injection of PEGylated Liposomes in Rats Elicits PEG-Specific IgM, Which Is Responsible for Rapid Elimination of a Second Dose of PEGylated Liposomes J. Controlled Release 2006, 112, 15-25 10.1016/j.jconrel.2006.01.005
65. Wang, X. Y.; Ishida, T.; Kiwada, H. Anti-PEG IgM Elicited by Injection of Liposomes is Involved in the Enhanced Blood Clearance of a Subsequent Dose of PEGylated Liposomes J. Controlled Release 2007, 119, 236-244 10.1016/j.jconrel.2007.02.010
66. Ishida, T.; Wang, X.; Shimizu, T.; Nawata, K.; Kiwada, H. PEGylated Liposomes Elicit an Anti-PEG IgM Response in a T Cell-Independent Manner J. Controlled Release 2007, 122, 349-355 10.1016/j.jconrel.2007.05.015
67. Ishida, T.; Kiwada, H. Accelerated Blood Clearance (ABC) Phenomenon upon Repeated Injection of PEGylated Liposomes Int. J. Pharm. 2008, 354, 56-62 10.1016/j.ijpharm.2007.11.005
68. Amoozgar, Z.; Yeo, Y. Recent Advances in Stealth Coating of Nanoparticle Drug Delivery Systems Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2012, 4, 219-233 10.1002/wnan.1157
69. Mishra, S.; Webster, P.; Davis, M. E. PEGylation Significantly Affects Cellular Uptake and Intracellular Trafficking of Non-Viral Gene Delivery Particles Eur. J. Cell Biol. 2004, 83, 97-111 10.1078/0171-9335-00363
70. Hatakeyama, H.; Akita, H.; Harashima, H. A Multifunctional Envelope Type Nano Device (MEND) for Gene Delivery to Tumours Based on the EPR Effect: a Strategy for Overcoming the PEG Dilemma Adv. Drug Delivery Rev. 2011, 63, 152-160 10.1016/j.addr.2010.09.001
71. Hamad, I.; Hunter, A. C.; Szebeni, J.; Moghimi, S. M. Poly(ethylene glycol)s Generate Complement Activation Products in Human Serum Through Increased Alternative Pathway Turnover and a MASP-2-Dependent Process Mol. Immunol. 2008, 46, 225-232 10.1016/j.molimm.2008.08.276
72. Wolfrum, C.; Shi, S.; Jayaprakash, K. N.; Jayaraman, M.; Wang, G.; Pandey, R. K.; Rajeev, K. G.; Nakayama, T.; Charrise, K.; Ndungo, E. M.; Zimmermann, T.; Koteliansky, V.; Manoharan, M.; Stoffel, M. Mechanisms and Optimization of in Vivo Delivery of Lipophilic siRNAs Nat. Biotechnol. 2007, 25, 1149-1157 10.1038/nbt1339
73. Zhang, Z. H.; Cao, W. G.; Jin, H. L.; Lovell, J. F.; Yang, M.; Ding, L. L.; Chen, J.; Corbin, I.; Luo, Q. M.; Zheng, G. Biomimetic Nanocarrier for Direct Cytosolic Drug Delivery Angew. Chem., Int. Ed. 2009, 48, 9171-9175 10.1002/anie.200903112
74. Yang, M.; Jin, H. L.; Chen, J. A.; Ding, L. L.; Ng, K. K.; Lin, Q. Y.; Lovell, J. F.; Zhang, Z. H.; Zheng, G. Efficient Cytosolic Delivery of siRNA Using HDL-Mimicking Nanoparticles Small 2011, 7, 568-573 10.1002/smll.201001589
75. Lasagna-Reeves, C.; Gonzalez-Romero, D.; Barria, M. A.; Olmedo, I.; Clos, A.; Ramanujam, V. M. S.; Urayama, A.; Vergara, L.; Kogan, M. J.; Soto, C. Bioaccumulation and Toxicity of Gold Nanoparticles after Repeated Administration in Mice Biochem. Biophys. Res. Commun. 2010, 393, 649-655 10.1016/j.bbrc.2010.02.046
76. Chen, Y. S.; Hung, Y. C.; Liau, I.; Huang, G. S. Assessment of the in Vivo Toxicity of Gold Nanoparticles Nanoscale Res. Lett. 2009, 4, 858-864 10.1007/s11671-009-9334-6
77. Anselmo, A. C.; Mitragotri, S. A Review of Clinical Translation of Inorganic Nanoparticles AAPS J. 2015, 17, 1041-1054 10.1208/s12248-015-9780-2
78. Allen, T. M.; Cullis, P. R. Liposomal Drug Delivery Systems: from Concept to Clinical Applications Adv. Drug Delivery Rev. 2013, 65, 36-48 10.1016/j.addr.2012.09.037
79. Danhier, F.; Ansorena, E.; Silva, J. M.; Coco, R.; Le Breton, A.; Preat, V. PLGA-Based Nanoparticles: an Overview of Biomedical Applications J. Controlled Release 2012, 161, 505-22 10.1016/j.jconrel.2012.01.043
80. Kamaly, N.; Xiao, Z. Y.; Valencia, P. M.; Radovic-Moreno, A. F.; Farokhzad, O. C. Targeted Polymeric Therapeutic Nanoparticles: Design, Development and Clinical Translation Chem. Soc. Rev. 2012, 41, 2971-3010 10.1039/c2cs15344k
81. Gong, J.; Chen, M.; Zheng, Y.; Wang, S.; Wang, Y. Polymeric Micelles Drug Delivery System in Oncology J. Controlled Release 2012, 159, 312-23 10.1016/j.jconrel.2011.12.012
82. Yokoyama, M. Polymeric Micelles as Drug Carriers: Their Lights and Shadows J. Drug Target. 2014, 22, 576-83 10.3109/1061186X.2014.934688
83. Cui, L. Y.; Lin, Q. Y.; Jin, C. S.; Jiang, W. L.; Huang, H.; Ding, L. L.; Muhanna, N.; Irish, J. C.; Wang, F.; Chen, J.; Zheng, G. A PEGylation-Free Biomimetic Porphyrin Nanoplatform for Personalized Cancer Theranostics ACS Nano 2015, 9, 4484-4495 10.1021/acsnano.5b01077
84. Ng, K. K.; Lovell, J. F.; Zheng, G. Lipoprotein-Inspired Nanoparticles for Cancer Theranostics Acc. Chem. Res. 2011, 44, 1105-1113 10.1021/ar200017e
85. Klibanov, A. L.; Maruyama, K.; Torchilin, V. P.; Huang, L. Amphipathic Polyethyleneglycols Effectively Prolong The Circulation Time of Liposomes FEBS Lett. 1990, 268, 235-7 10.1016/0014-5793(90)81016-H
86. Allen, T. M.; Hansen, C.; Martin, F.; Redemann, C.; Yau-Young, A. Liposomes Containing Synthetic Lipid Derivatives of Poly(ethylene glycol) Show Prolonged Circulation Half-lives in Vivo Biochim. Biophys. Acta, Biomembr. 1991, 1066, 29-36 10.1016/0005-2736(91)90246-5
87. Sanchez-Gaytan, B. L.; Fay, F.; Lobatto, M. E.; Tang, J.; Ouimet, M.; Kim, Y.; van der Staay, S. E.; van Rijs, S. M.; Priem, B.; Zhang, L.; Fisher, E. A.; Moore, K. J.; Langer, R.; Fayad, Z. A.; Mulder, W. J. HDL-Mimetic PLGA Nanoparticle to Target Atherosclerosis Plaque Macrophages Bioconjugate Chem. 2015, 26, 443-51 10.1021/bc500517k
88. Cormode, D. P.; Briley-Saebo, K. C.; Mulder, W. J. M.; Aguinaldo, J. G. S.; Barazza, A.; Ma, Y. Q.; Fisher, E. A.; Fayad, Z. A. An ApoA-I Mimetic Peptide High-Density-Lipoprotein-Based MRI Contrast Agent for Atherosclerotic Plaque Composition Detection Small 2008, 4, 1437-1444 10.1002/smll.200701285
89. Hirsch, L. R.; Stafford, R. J.; Bankson, J. A.; Sershen, S. R.; Rivera, B.; Price, R. E.; Hazle, J. D.; Halas, N. J.; West, J. L. Nanoshell-Mediated Near-Infrared Thermal Therapy of Tumors under Magnetic Resonance Guidance Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 13549-13554 10.1073/pnas.2232479100
90. Gad, S. C.; Sharp, K. L.; Montgomery, C.; Payne, J. D.; Goodrich, G. P. Evaluation of the Toxicity of Intravenous Delivery of Auroshell Particles (Gold-Silica Nanoshells) Int. J. Toxicol. 2012, 31, 584-94 10.1177/1091581812465969
91. Schwartz, J. A.; Shetty, A. M.; Price, R. E.; Stafford, R. J.; Wang, J. C.; Uthamanthil, R. K.; Pham, K.; McNichols, R. J.; Coleman, C. L.; Payne, J. D. Feasibility Study of Particle-Assisted Laser Ablation of Brain Tumors in Orthotopic Canine Model Cancer Res. 2009, 69, 1659-1667 10.1158/0008-5472.CAN-08-2535
92. Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck. https://clinicaltrials.gov/ct2/show/NCT00848042.
93. Efficacy Study of AuroLase Therapy in Subjects with Primary and/or Metastatic Lung Tumors. https://www.clinicaltrials.gov/ct2/show/NCT01679470?term=NCT01679470&rank=1.
94. Libutti, S. K.; Paciotti, G. F.; Byrnes, A. A.; Alexander, H. R.; Gannon, W. E.; Walker, M.; Seidel, G. D.; Yuldasheva, N.; Tamarkin, L. Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine Clin. Cancer Res. 2010, 16, 6139-6149 10.1158/1078-0432.CCR-10-0978
95. Mclachlan, S. J.; Morris, M. R.; Lucas, M. A.; Fisco, R. A.; Eakins, M. N.; Fowler, D. R.; Scheetz, R. B.; Olukotun, A. Y. Phase-I Clinical-Evaluation of a New Iron-Oxide Mr Contrast Agent J. Magn. Reson. Imaging 1994, 4, 301-307 10.1002/jmri.1880040313
96. Bellin, M. F.; Roy, C.; Kinkel, K.; Thoumas, D.; Zaim, S.; Vanel, D.; Tuchmann, C.; Richard, F.; Jacqmin, D.; Delcourt, A.; Challier, E.; Lebret, T.; Cluzel, P. Lymph Node Metastases: Safety and Effectiveness of MR Imaging with Ultrasmall Superparamagnetic Iron Oxide Particles-Initial Clinical Experience Radiology 1998, 207, 799-808 10.1148/radiology.207.3.9609907
97. Maier-Hauff, K.; Ulrich, F.; Nestler, D.; Niehoff, H.; Wust, P.; Thiesen, B.; Orawa, H.; Budach, V.; Jordan, A. Efficacy and Safety of Intratumoral Thermotherapy Using Magnetic Iron-Oxide Nanoparticles Combined with External Beam Radiotherapy on Patients with Recurrent Glioblastoma Multiforme J. Neuro-Oncol. 2011, 103, 317-324 10.1007/s11060-010-0389-0
98. Hahn, P. F.; Stark, D. D.; Lewis, J. M.; Saini, S.; Elizondo, G.; Weissleder, R.; Fretz, C. J.; Ferrucci, J. T. First Clinical Trial of a New Superparamagnetic Iron Oxide for Use as an Oral Gastrointestinal Contrast Agent in MR Imaging Radiology 1990, 175, 695-700 10.1148/radiology.175.3.2343116
99. Spinowitz, B. S.; Schwenk, M. H.; Jacobs, P. M.; Bolton, W. K.; Kaplan, M. R.; Charytan, C.; Galler, M. The Safety and Efficacy of Ferumoxytol Therapy in Anemic Chronic Kidney Disease Patients Kidney Int. 2005, 68, 1801-1807 10.1111/j.1523-1755.2005.00598.x
100. Singh, A.; Patel, T.; Hertel, J.; Bernardo, M.; Kausz, A.; Brenner, L. Safety of Ferumoxytol in Patients With Anemia and CKD Am. J. Kidney Dis. 2008, 52, 907-915 10.1053/j.ajkd.2008.08.001
101. Phillips, E.; Penate-Medina, O.; Zanzonico, P. B.; Carvajal, R. D.; Mohan, P.; Ye, Y. P.; Humm, J.; Gonen, M.; Kalaigian, H.; Schoder, H.; Strauss, H. W.; Larson, S. M.; Wiesner, U.; Bradbury, M. S. Clinical Translation of an Ultrasmall Inorganic Optical-PET Imaging Nanoparticle Probe Sci. Transl. Med. 2014, 6, 260ra149 10.1126/scitranslmed.3009524
102. Duivenvoorden, R.; Tang, J.; Cormode, D. P.; Mieszawska, A. J.; Izquierdo-Garcia, D.; Ozcan, C.; Otten, M. J.; Zaidi, N.; Lobatto, M. E.; van Rijs, S. M.; Priem, B.; Kuan, E. L.; Martel, C.; Hewing, B.; Sager, H.; Nahrendorf, M.; Randolph, G. J.; Stroes, E. S. G.; Fuster, V.; Fisher, E. A. A Statin-Loaded Reconstituted High-Density Lipoprotein Nanoparticle Inhibits Atherosclerotic Plaque Inflammation Nat. Commun. 2014, 5, 3065 10.1038/ncomms4065
103. Argraves, K. M.; Gazzolo, P. J.; Groh, E. M.; Wilkerson, B. A.; Matsuura, B. S.; Twal, W. O.; Hammad, S. M.; Argraves, W. S. High Density Lipoprotein-Associated Sphingosine 1-Phosphate Promotes Endothelial Barrier Function J. Biol. Chem. 2008, 283, 25074-25081 10.1074/jbc.M801214200
104. de Vrueh, R. L. A.; Rump, E. T.; van de Bilt, E.; van Veghel, R.; Balzarini, J.; Biessen, E. A. L.; van Berkel, T. J. C.; Bijsterbosch, M. K. Carrier-Mediated Delivery of 9-(2-phosphonylmethoxyethyl)adenine to Parenchymal Liver Cells: a Novel Therapeutic Approach for Hepatitis B Antimicrob. Agents Chemother. 2000, 44, 477-483 10.1128/AAC.44.3.477-483.2000
105. Oda, M. N.; Hargreaves, P. L.; Beckstead, J. A.; Redmond, K. A.; van Antwerpen, R.; Ryan, R. O. Reconstituted High Density Lipoprotein Enriched with the Polyene Antibiotic Amphotericin B J. Lipid Res. 2006, 47, 260-267 10.1194/jlr.D500033-JLR200
106. Zhang, X. B.; Chen, B. S. Recombinant High Density Lipoprotein Reconstituted with Apolipoprotein AI Cysteine Mutants as Delivery Vehicles for 10-Hydroxycamptothecin Cancer Lett. 2010, 298, 26-33 10.1016/j.canlet.2010.05.023
107. Singh, A. T. K.; Evens, A. M.; Anderson, R. J.; Beckstead, J. A.; Sankar, N.; Sassano, A.; Bhalla, S.; Yang, S.; Platanias, L. C.; Forte, T. M.; Ryan, R. O.; Gordon, L. I. All Trans Retinoic Acid Nanodisks Enhance Retinoic Acid Receptor Mediated Apoptosis and Cell Cycle Arrest in Mantle Cell Lymphoma Br. J. Hamaetol. 2010, 150, 158-169
108. Ghosh, M.; Singh, A. T. K.; Xu, W. W.; Sulchek, T.; Gordon, L. I.; Ryan, R. O. Curcumin Nanodisks: Formulation and Characterization Nanomedicine 2011, 7, 162-167 10.1016/j.nano.2010.08.002
109. Singh, A. T. K.; Ghosh, M.; Forte, T. M.; Ryan, R. O.; Gordon, L. I. Curcumin Nanodisk-Induced Apoptosis in Mantle Cell Lymphoma Leuk. Lymphoma 2011, 52, 1537-1543 10.3109/10428194.2011.584253
110. McConathy, W. J.; Nair, M. P.; Paranjape, S.; Mooberry, L.; Lacko, A. G. Evaluation of Synthetic/Reconstituted High-Density Lipoproteins as Delivery Vehicles for Paclitaxel Anti-Cancer Drugs 2008, 19, 183-188 10.1097/CAD.0b013e3282f1da86
111. Mooberry, L. K.; Nair, M.; Paranjape, S.; McConathy, W. J.; Lacko, A. G. Receptor Mediated Uptake of Paclitaxel from a Synthetic High Density Lipoprotein Nanocarrier J. Drug Target. 2010, 18, 53-58 10.3109/10611860903156419
112. Yuan, Y.; Wang, W. N.; Wang, B. L.; Zhu, H. Y.; Zhang, B. H.; Feng, M. Q. Delivery of Hydrophilic Drug Doxorubicin Hydrochloride-Targeted Liver Using ApoAI as Carrier J. Drug Target. 2013, 21, 367-374 10.3109/1061186X.2012.757769
113. Weilhammer, D. R.; Blanchette, C. D.; Fischer, N. O.; Alam, S.; Loots, G. G.; Corzett, M.; Thomas, C.; Lychak, C.; Dunkle, A. D.; Ruitenberg, J. J.; Ghanekar, S. A.; Sant, A. J.; Rasley, A. The Use of Nanolipoprotein Particles to Enhance the Immunostimulatory Properties of Innate Immune Agonists Against Lethal Influenza Challenge Biomaterials 2013, 34, 10305-10318 10.1016/j.biomaterials.2013.09.038
114. Feng, M. Q.; Cai, Q. S.; Shi, X. L.; Huang, H.; Zhou, P.; Guo, X. Recombinant High-Density Lipoprotein Complex as a Targeting System of Nosiheptide to Liver Cells J. Drug Target. 2008, 16, 502-508 10.1080/10611860802200938
115. Kim, S. K.; Foote, M. B.; Huang, L. The Targeted Intracellular Delivery of Cytochrome C Protein to Tumors Using Lipid-Apolipoprotein Nanoparticles Biomaterials 2012, 33, 3959-3966 10.1016/j.biomaterials.2012.02.010
116. Huang, C.; Jin, H. L.; Qian, Y.; Qi, S. H.; Luo, H. M.; Luo, Q. M.; Zhang, Z. H. Hybrid Melittin Cytolytic Peptide-Driven Ultrasmall Lipid Nanoparticles Block Melanoma Growth in Vivo ACS Nano 2013, 7, 5791-5800 10.1021/nn400683s
117. Fischer, N. O.; Rasley, A.; Corzett, M.; Hwang, M. H.; Hoeprich, P. D.; Blanchette, C. D. Colocalized Delivery of Adjuvant and Antigen Using Nanolipoprotein Particles Enhances the Immune Response to Recombinant Antigens J. Am. Chem. Soc. 2013, 135, 2044-2047 10.1021/ja3063293
118. Fischer, N. O.; Rasley, A.; Corzett, M.; Hwang, M. H.; Hoeprich, P. D.; Blanchette, C. D. Colocalized delivery of adjuvant and antigen using nanolipoprotein particles enhances the immune response to recombinant antigens J. Am. Chem. Soc. 2013, 135, 2044-7 10.1021/ja3063293
119. Nakayama, T.; Butler, J. S.; Sehgal, A.; Severgnini, M.; Racie, T.; Sharman, J.; Ding, F.; Morskaya, S. S.; Brodsky, J.; Tchangov, L.; Kosovrasti, V.; Meys, M.; Nechev, L.; Wang, G.; Peng, C. G.; Fang, Y. P.; Maier, M.; Rajeev, K. G.; Li, R.; Hettinger, J. et al. Harnessing a Physiologic Mechanism for siRNA Delivery With Mimetic Lipoprotein Particles Mol. Ther. 2012, 20, 1582-1589 10.1038/mt.2012.33
120. Shahzad, M. M. K.; Mangala, L. S.; Han, H. D.; Lu, C. H.; Bottsford-Miller, J.; Nishimura, M.; Mora, E. M.; Lee, J. W.; Stone, R. L.; Pecot, C. V.; Thanapprapasr, D.; Roh, J. W.; Gaur, P.; Nair, M. P.; Park, Y. Y.; Sabnis, N.; Deavers, M. T.; Lee, J. S.; Ellis, L. M.; Lopez-Berestein, G. et al. Targeted Delivery of Small Interfering RNA Using Reconstituted High-Density Lipoprotein Nanoparticles Neoplasia 2011, 13, 309-U142 10.1593/neo.101372
121. Kuwahara, H.; Nishina, K.; Yoshida, K.; Nishina, T.; Yamamoto, M.; Saito, Y.; Piao, W. Y.; Yoshida, M.; Mizusawa, H.; Yokota, T. Efficient in Vivo Delivery of siRNA into Brain Capillary Endothelial Cells along With Endogenous Lipoprotein Mol. Ther. 2011, 19, 2213-2221 10.1038/mt.2011.186
122. Libby, P.; Ridker, P. M.; Hansson, G. K. Progress and Challenges in Translating the Biology of Atherosclerosis Nature 2011, 473, 317-325 10.1038/nature10146
123. Vanderwal, A. C.; Becker, A. E.; Vanderloos, C. M.; Das, P. K. Site of Intimal Rupture or Erosion of Thrombosed Coronary Atherosclerotic Plaques Is Characterized by an Inflammatory Process Irrespective of the Dominant Plaque Morphology Circulation 1994, 89, 36-44 10.1161/01.CIR.89.1.36
124. Weber, C.; Noels, H. Atherosclerosis: Current Pathogenesis and Therapeutic Options Nat. Med. 2011, 17, 1410-1422 10.1038/nm.2538
125. Zhang, W. L.; He, H. L.; Liu, J. P.; Wang, J.; Zhang, S. Y.; Zhang, S. S.; Wu, Z. M. Pharmacokinetics and Atherosclerotic Lesions Targeting Effects of Tanshinone IIA Discoidal and Spherical Biomimetic High Density Lipoproteins Biomaterials 2013, 34, 306-319 10.1016/j.biomaterials.2012.09.058
126. Moulton, K. S.; Olsen, B. R.; Sonn, S.; Fukai, N.; Zurakowski, D.; Zeng, X. K. Loss of Collagen XVIII Enhances Neovascularization and Vascular Permeability in Atherosclerosis Circulation 2004, 110, 1330-1336 10.1161/01.CIR.0000140720.79015.3C
127. Rader, D. J. Molecular regulation of HDL metabolism and function: implications for novel therapies J. Clin. Invest. 2006, 116, 3090-100 10.1172/JCI30163
128. Zhang, W. L.; Xiao, Y.; Liu, J. P.; Wu, Z. M.; Gu, X.; Xu, Y. M.; Lu, H. Structure and Remodeling Behavior of Drug-loaded High Density Lipoproteins and Their Aerosclerotic Plaque Targeting Mechanism in Foam Cell Model Int. J. Pharm. 2011, 419, 314-321 10.1016/j.ijpharm.2011.07.039
129. Poelstra, K.; Prakash, J.; Beljaars, L. Drug Targeting to the Diseased Liver J. Controlled Release 2012, 161, 188-197 10.1016/j.jconrel.2012.02.011
130. Smith, J. S.; Xu, Z. L.; Byrnes, A. P. A Quantitative Assay for Measuring Clearance of Adenovirus Vectors by Kupffer Cells J. Virol. Methods 2008, 147, 54-60 10.1016/j.jviromet.2007.08.009
131. Wang, H. X.; Xiong, M. H.; Wang, Y. C.; Zhu, J.; Wang, J. N-acetylgalactosamine Functionalized Mixed Micellar Nanoparticles for Targeted Delivery of siRNA to Liver J. Controlled Release 2013, 166, 106-114 10.1016/j.jconrel.2012.12.017
132. Tian, Q.; Zhang, C. N.; Wang, X. H.; Wang, W.; Huang, W.; Cha, R. T.; Wang, C. H.; Yuan, Z.; Liu, M.; Wan, H. Y.; Tang, H. Glycyrrhetinic Acid-Modified Chitosan/Poly(ethylene glycol) Nanoparticles for Liver-Targeted Delivery Biomaterials 2010, 31, 4748-4756 10.1016/j.biomaterials.2010.02.042
133. Hirata, K.; Maruyama, T.; Watanabe, H.; Maeda, H.; Nakajou, K.; Iwao, Y.; Ishima, Y.; Katsumi, H.; Hashida, M.; Otagiri, M. Genetically Engineered Mannosylated-Human Serum Albumin as a Versatile Carrier for Liver-Selective Therapeutics J. Controlled Release 2010, 145, 9-16 10.1016/j.jconrel.2010.03.010
134. Deng, Q.; Mancini-Bourgine, M.; Zhang, X. M.; Cumont, M. C.; Zhu, R.; Lone, Y. C.; Michel, M. L. Hepatitis B Virus As a Gene Delivery Vector Activating Foreign Antigenic T Cell Response that Abrogates Viral Expression in Mouse Models Hepatology 2009, 50, 1380-1391 10.1002/hep.23150
135. Giacca, M.; Zacchigna, S. Virus-Mediated Gene Delivery for Human Gene Therapy J. Controlled Release 2012, 161, 377-388 10.1016/j.jconrel.2012.04.008
136. Rensen, P. C. N.; de Vrueh, R. L. A.; Kuiper, J.; Bijsterbosch, M. K.; Biessen, E. A. L.; van Berkel, T. J. C. Recombinant Lipoproteins: Lipoprotein-Like Lipid Particles for Drug Targeting Adv. Drug Delivery Rev. 2001, 47, 251-276 10.1016/S0169-409X(01)00109-0
137. Gullotti, E.; Yeo, Y. Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery Mol. Pharmaceutics 2009, 6, 1041-1051 10.1021/mp900090z
138. Eisenberg, S.; Windmueller, H. G.; Levy, R. I. Metabolic Fate of Rat and Human Lipoprotein Apoproteins in the Rat J. Lipid Res. 1973, 14, 446-58
139. Pluen, A.; Boucher, Y.; Ramanujan, S.; McKee, T. D.; Gohongi, T.; di Tomaso, E.; Brown, E. B.; Izumi, Y.; Campbell, R. B.; Berk, D. A.; Jain, R. K. Role of Tumor-Host Interactions in Interstitial Diffusion of Macromolecules: Cranial vs. Subcutaneous Tumors Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 4628-4633 10.1073/pnas.081626898
140. Siperstein, M. D. Role of Cholesterogenesis and Isoprenoid Synthesis in DNA-Replication and Cell-Growth J. Lipid Res. 1984, 25, 1462-1468
141. Hynds, S. A.; Welsh, J.; Stewart, J. M.; Jack, A.; Soukop, M.; Mcardle, C. S.; Calman, K. C.; Packard, C. J.; Shepherd, J. Low-Density Lipoprotein Metabolism in Mice with Soft-Tissue Tumors Biochim. Biophys. Acta, Lipids Lipid Metab. 1984, 795, 589-595 10.1016/0005-2760(84)90189-9
142. Vitols, S.; Norgren, S.; Juliusson, G.; Tatidis, L.; Luthman, H. Multilevel Regulation of Low-Density-Lipoprotein Receptor and 3-Hydroxy-3-Methylglutaryl Coenzyme-a Reductase Gene-Expression in Normal and Leukemic-Cells Blood 1994, 84, 2689-2698
143. Pussinen, P. J.; Karten, B.; Wintersperger, A.; Reicher, H.; McLean, M.; Malle, E.; Sattler, W. The Human Breast Carcinoma Cell Line HBL-100 Acquires Exogenous Cholesterol from High-Density Lipoprotein via CLA-1 (CD-36 and LIMPII Analogous 1)-Mediated Selective Cholesteryl Ester Uptake Biochem. J. 2000, 349, 559-566 10.1042/0264-6021:3490559
144. Imachi, H.; Murao, K.; Sayo, Y.; Hosokawa, H.; Sato, M.; Niimi, M.; Kobayashi, S.; Miyauchi, A.; Ishida, T.; Takahara, J. Evidence for a Potential Role for HDL as an Important Source of Cholesterol in Human Adrenocortical Tumors via the CLA-1 Pathway Endocr. J. 1999, 46, 27-34 10.1507/endocrj.46.27
145. Leon, C. G.; Locke, J. A.; Adomat, H. H.; Etinger, S. L.; Twiddy, A. L.; Neumann, R. D.; Nelson, C. C.; Guns, E. S.; Wasan, K. M. Alterations in Cholesterol Regulation Contribute to the Production of Intratumoral Androgens During Progression to Castration-Resistant Prostate Cancer in a Mouse Xenograft Model Prostate 2010, 70, 390-400 10.1002/pros.21072
146. Zhang, Z. H.; Chen, J.; Ding, L. L.; Jin, H. L.; Lovell, J. F.; Corbin, I. R.; Cao, W. G.; Lo, P. C.; Yang, M.; Tsao, M. S.; Luo, Q. M.; Zheng, G. HDL-Mimicking Peptide-Lipid Nanoparticles with Improved Tumor Targeting Small 2010, 6, 430-437 10.1002/smll.200901515
147. Chen, W.; Jarzyna, P. A.; van Tilborg, G. A. F.; Nguyen, V. A.; Cormode, D. P.; Klink, A.; Griffioen, A. W.; Randolph, G. J.; Fisher, E. A.; Mulder, W. J. M.; Fayad, Z. A. RGD Peptide Functionalized and Reconstituted High-Density Lipoprotein Nanoparticles as a Versatile and Multimodal Tumor Targeting Molecular Imaging Probe FASEB J. 2010, 24, 1689-1699 10.1096/fj.09-139865
148. Corbin, I. R.; Ng, K. K.; Ding, L. L.; Jurisicova, A.; Zheng, G. Near-Infrared Fluorescent Imaging of Metastatic Ovarian Cancer Using Folate Receptor-Targeted High-Density Lipoprotein Nanocarriers Nanomedicine 2013, 8, 875-890 10.2217/nnm.12.137
149. Corbin, I. R.; Chen, J.; Cao, W.; Li, H.; Lund-Katz, S.; Zheng, G. Enhanced Cancer-Targeted Delivery Using Engineered High-Density Lipoprotein-Based Nanocarriers J. Biomed. Nanotechnol. 2007, 3, 367-376 10.1166/jbn.2007.053
150. Mellman, I.; Coukos, G.; Dranoff, G. Cancer Immunotherapy Comes of Age Nature 2011, 480, 480-9 10.1038/nature10673
151. Joshi, M. D.; Unger, W. J.; Storm, G.; van Kooyk, Y.; Mastrobattista, E. Targeting Tumor Antigens to Dendritic Cells Using Particulate Carriers J. Controlled Release 2012, 161, 25-37 10.1016/j.jconrel.2012.05.010
152. Beutler, B. Inferences, 1uestions and Possibilities in Toll-like Receptor Signalling Nature 2004, 430, 257-263 10.1038/nature02761
153. Lawton, J. A.; Ghosh, P. Novel Therapeutic Strategies Based on Toll-Like Receptor Signaling Curr. Opin. Chem. Biol. 2003, 7, 446-451 10.1016/S1367-5931(03)00077-2
154. Sahdev, P.; Ochyl, L. J.; Moon, J. J. Biomaterials for Nanoparticle Vaccine Delivery Systems Pharm. Res. 2014, 31, 2563-2582 10.1007/s11095-014-1419-y
155. Wilson, J. T.; Keller, S.; Manganiello, M. J.; Cheng, C.; Lee, C. C.; Opara, C.; Convertine, A.; Stayton, P. S. pH-Responsive Nanoparticle Vaccines for Dual-Delivery of Antigens and Immunostimulatory Oligonucleotides ACS Nano 2013, 7, 3912-3925 10.1021/nn305466z
156. Yuba, E.; Harada, A.; Sakanishi, Y.; Watarai, S.; Kono, K. A Liposome-Based Antigen Delivery System Using pH-Sensitive Fusogenic Polymers for Cancer Immunotherapy Biomaterials 2013, 34, 3042-3052 10.1016/j.biomaterials.2012.12.031
157. Hamdy, S.; Haddadi, A.; Hung, R. W.; Lavasanifar, A. Targeting Dendritic Cells with Nano-Particulate PLGA Cancer Vaccine Formulations Adv. Drug Delivery Rev. 2011, 63, 943-955 10.1016/j.addr.2011.05.021
158. Fischer, N. O.; Blanchette, C.; Rasley, A. Enhancing the Efficacy of Innate Immune Agonists: Could Nanolipoprotein Particles Hold the Key? Nanomedicine 2014, 9, 369-372 10.2217/nnm.14.15
159. Kuai, R.; Ochyl, L. J.; Schwendeman, A.; Moon, J. J. Lipid-Based Nanoparticles for Vaccine Applications. In Biomedical Engineering: Frontier Research and Converging Technologies; Jo, H.; Jun, H. W.; Shin, J.; Lee, S.-H., Eds.; Springer, 2016; Vol. 9, pp 177-197.
160. Bachmann, M. F.; Jennings, G. T. Vaccine Delivery: a Matter of Size, Geometry, Kinetics and Molecular Patterns Nat. Rev. Immunol. 2010, 10, 787-796 10.1038/nri2868
161. Krishnamachari, Y.; Salem, A. K. Innovative Strategies for Co-delivering Antigens and CpG Oligonucleotides Adv. Drug Delivery Rev. 2009, 61, 205-217 10.1016/j.addr.2008.12.013
162. Mutwiri, G. K.; Nichani, A. K.; Babiuk, S.; Babiuk, L. A. Strategies for Enhancing the Immunostimulatory Effects of CpG Oligodeoxynucleotides J. Controlled Release 2004, 97, 1-17 10.1016/j.jconrel.2004.02.022
163. Hogquist, K. A.; Baldwin, T. A.; Jameson, S. C. Central Tolerance: Learning Self-Control in the Thymus Nat. Rev. Immunol. 2005, 5, 772-782 10.1038/nri1707
164. Mueller, D. L. Mechanisms Maintaining Peripheral Tolerance Nat. Immunol. 2010, 11, 21-27 10.1038/ni.1817
165. Norata, G. D.; Pirillo, A.; Ammirati, E.; Catapano, A. L. Emerging role of High Density Lipoproteins as a Player in the Immune System Atherosclerosis 2012, 220, 11-21 10.1016/j.atherosclerosis.2011.06.045
166. Blaho, V. A.; Galvani, S.; Engelbrecht, E.; Liu, C.; Swendeman, S. L.; Kono, M.; Proia, R. L.; Steinman, L.; Han, M. H.; Hla, T. HDL-Bound Sphingosine-1-Phosphate Restrains Lymphopoiesis and Neuroinflammation Nature 2015, 523, 342-346 10.1038/nature14462
167. Hatch, F. T. Practical Methods for Plasma Lipoprotein Analysis. Advances in Lipid Research; Elsevier, 1968; Vol. 6, pp 1-68.
168. van den Elzen, P.; Garg, S.; Leon, L.; Brigl, M.; Leadbetter, E. A.; Gumperz, J. E.; Dascher, C. C.; Cheng, T. Y.; Sacks, F. M.; Illarionov, P. A.; Besra, G. S.; Kent, S. C.; Moody, D. B.; Brenner, M. B. Apolipoprotein-Mediated Pathways of Lipid Antigen Presentation Nature 2005, 437, 906-910 10.1038/nature04001
169. Kim, Y.; Fay, F.; Cormode, D. P.; Sanchez-Gaytan, B. L.; Tang, J.; Hennessy, E. J.; Ma, M. M.; Moore, K.; Farokhzad, O. C.; Fisher, E. A.; Mulder, W. J. M.; Langer, R.; Fayad, Z. A. Single Step Reconstitution of Multifunctional High-Density Lipoprotein-Derived Nanomaterials Using Microfluidics ACS Nano 2013, 7, 9975-9983 10.1021/nn4039063
170. Rudman, D.; Hollins, B.; Bixler, T. J.; Mostelle, Rc Transport of Drugs, Hormones and Fatty-Acids in Lipemic Serum J. Pharmacol. Exp. Ther. 1972, 180, 797
171. Counsell, R. E.; Pohland, R. C. Lipoproteins as Potential Site-Specific Delivery Systems for Diagnostic and Therapeutic Agents J. Med. Chem. 1982, 25, 1115-1120 10.1021/jm00352a001
172. Goldstein, J. L.; Brown, M. S. Regulation of the Mevalonate Pathway Nature 1990, 343, 425-430 10.1038/343425a0
173. Lefer, D. J. Statins as Potent Anti-Inflammatory Drugs Circulation 2002, 106, 2041-2042 10.1161/01.CIR.0000033635.42612.88
174. Kwak, B.; Mulhaupt, F.; Myit, S.; Mach, F. Statins as a Newly Recognized Type of Immunomodulator Nat. Med. 2000, 6, 1399-1402 10.1038/82219
175. Armitage, J. The Safety of Statins in Clinical Practice Lancet 2007, 370, 1781-1790 10.1016/S0140-6736(07)60716-8
176. Nicoll, A. J.; Colledge, D. L.; Toole, J. J.; Angus, P. W.; Smallwood, R. A.; Locarnini, S. A. Inhibition of Duck Hepatitis B Virus Replication by 9-(2-phosphonylmethoxyethyl)adenine, an Acyclic Phosphonate Nucleoside Analogue Antimicrob. Agents Chemother. 1998, 42, 3130-3135
177. Yokota, T.; Mochizuki, S.; Konno, K.; Mori, S.; Shigeta, S.; Declercq, E. Inhibitory Effects of Selected Antiviral Compounds on Human Hepatitis-B Virus-DNA Synthesis Antimicrob. Agents Chemother. 1991, 35, 394-397 10.1128/AAC.35.2.394
178. Naesens, L.; Balzarini, J.; Declercq, E. Pharmacokinetics in Mice of the Antiretrovirus Agent 9-(2-Phosphonylmethoxyethyl)Adenine Drug Metab. Dispos. 1992, 20, 747-752
179. Wall, M. E. Camptothecin and Taxol: Discovery to Clinic Med. Res. Rev. 1998, 18, 299-314 10.1002/(SICI)1098-1128(199809)18:5<299::AID-MED2>3.0.CO;2-O
180. Wang, A.; Li, S. Hydroxycamptothecin-Loaded Nanoparticles Enhance Target Drug Delivery and Anticancer Effect BMC Biotechnol. 2008, 8, 46 10.1186/1472-6750-8-46
181. Sattler, K.; Levkau, B. Sphingosine-1-Phosphate as a Mediator of High-Density Lipoprotein Effects in Cardiovascular Protection Cardiovasc. Res. 2009, 82, 201-211 10.1093/cvr/cvp070
182. Manning, M. C.; Chou, D. K.; Murphy, B. M.; Payne, R. W.; Katayama, D. S. Stability of Protein Pharmaceuticals: An Update Pharm. Res. 2010, 27, 544-575 10.1007/s11095-009-0045-6
183. Tabata, Y.; Ikada, Y. Protein Release from Gelatin Matrices Adv. Drug Delivery Rev. 1998, 31, 287-301 10.1016/S0169-409X(97)00125-7
184. Shah, A. S.; Tan, L.; Long, J. L.; Davidson, W. S. Thematic Review Series: High Density Lipoprotein Structure, Function, and Metabolism Proteomic Diversity of High Density Lipoproteins: Our Emerging Understanding of Its Importance in Lipid Transport and Beyond J. Lipid Res. 2013, 54, 2575-2585 10.1194/jlr.R035725
185. Benazet, F.; Cartier, M.; Florent, J.; Godard, C.; Jung, G.; Lunel, J.; Mancy, D.; Pascal, C.; Renaut, J.; Tarridec, P.; Theilleux, J.; Tissier, R.; Dubost, M.; Ninet, L. Nosiheptide, a Sulfur-Containing Peptide Antibiotic Isolated from Streptomyces-Actuosus 40037 Experientia 1980, 36, 414-416 10.1007/BF01975121
186. Papo, N.; Shai, Y. Host Defense Peptides as New Weapons in Cancer Treatment Cell. Mol. Life Sci. 2005, 62, 784-790 10.1007/s00018-005-4560-2
187. Liu, S. J.; Yu, M.; He, Y.; Xiao, L.; Wang, F.; Song, C. C.; Sun, S. H.; Ling, C. Q.; Xu, Z. H. Melittin Prevents Liver Cancer Cell Metastasis through Inhibition of the Rac1-Dependent Pathway Hepatology 2008, 47, 1964-1973 10.1002/hep.22240
188. Aguilar, J. C.; Rodriguez, E. G. Vaccine Adjuvants Revisited Vaccine 2007, 25, 3752-3762 10.1016/j.vaccine.2007.01.111
189. Xu, Z. H.; Ramishetti, S.; Tseng, Y. C.; Guo, S. T.; Wang, Y. H.; Huang, L. Multifunctional Nanoparticles Co-delivering Trp2 Peptide and CpG Adjuvant Induce Potent Cytotoxic T-Lymphocyte Response Against Melanoma and Its Lung Metastasis J. Controlled Release 2013, 172, 259-265 10.1016/j.jconrel.2013.08.021
190. Molino, N. M.; Anderson, A. K. L.; Nelson, E. L.; Wang, S. W. Biomimetic Protein Nanoparticles Facilitate Enhanced Dendritic Cell Activation and Cross-Presentation ACS Nano 2013, 7, 9743-9752 10.1021/nn403085w
191. Fischer, N. O.; Infante, E.; Ishikawa, T.; Blanchette, C. A.; Bourne, N.; Hoeprich, P. D.; Mason, P. W. Conjugation to Nickel-Chelating Nanolipoprotein Particles Increases the Potency and Efficacy of Subunit Vaccines to Prevent West Nile Encephalitis Bioconjugate Chem. 2010, 21, 1018-1022 10.1021/bc100083d
192. Fischer, N. O.; Blanchette, C. D.; Chromy, B. A.; Kuhn, E. A.; Segelke, B. W.; Corzett, M.; Bench, G.; Mason, P. W.; Hoeprich, P. D. Immobilization of His-Tagged Proteins on Nickel-Chelating Nanolipoprotein Particles Bioconjugate Chem. 2009, 20, 460-465 10.1021/bc8003155
193. Gomes-da-Silva, L. C.; Fonseca, N. A.; Moura, V.; de Lima, M. C. P.; Simoes, S.; Moreira, J. N. Lipid-Based Nanoparticles for siRNA Delivery in Cancer Therapy: Paradigms and Challenges Acc. Chem. Res. 2012, 45, 1163-1171 10.1021/ar300048p
194. Eder, P. S.; DeVine, R. J.; Dagle, J. M.; Walder, J. A. Substrate Specificity and Kinetics of Degradation of Antisense Oligonucleotides by a 3′ Exonuclease in Plasma Antisense Res. Dev. 1991, 1, 141-51
195. Kennedy, S.; Wang, D.; Ruvkun, G. A Conserved siRNA-Degrading RNase Negatively Regulates RNA Interference in C-elegans Nature 2004, 427, 645-649 10.1038/nature02302
196. Guo, S. T.; Huang, L. Nanoparticles Escaping RES and Endosome: Challenges for siRNA Delivery for Cancer Therapy J. Nanomater. 2011, 2011, 1 10.1155/2011/742895
197. Chendrimada, T. P.; Gregory, R. I.; Kumaraswamy, E.; Norman, J.; Cooch, N.; Nishikura, K.; Shiekhattar, R. TRBP Recruits the Dicer Complex to Ago2 for MicroRNA Processing and Gene Silencing Nature 2005, 436, 740-744 10.1038/nature03868
198. Matranga, C.; Tomari, Y.; Shin, C.; Bartel, D. P.; Zamore, P. D. Passenger-Strand Cleavage Facilitates Assembly of siRNA into Ago2-Containing RNAi Enzyme Complexes Cell 2005, 123, 607-620 10.1016/j.cell.2005.08.044
199. Behlke, M. A. Chemical Modification of siRNAs for in Vivo Use Oligonucleotides 2008, 18, 305-319 10.1089/oli.2008.0164
200. Frank-Kamenetsky, M.; Grefhorst, A.; Anderson, N. N.; Racie, T. S.; Bramlage, B.; Akinc, A.; Butler, D.; Charisse, K.; Dorkin, R.; Fan, Y.; Gamba-Vitalo, C.; Hadwiger, P.; Jayaraman, M.; John, M.; Jayaprakash, K. N.; Maier, M.; Nechev, L.; Rajeev, K. G.; Read, T.; Rohl, I. et al. Therapeutic RNAi Targeting PCSK9 Acutely Lowers Plasma Cholesterol in Rodents and LDL Cholesterol in Nonhuman Primates Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 11915-11920 10.1073/pnas.0805434105
201. Higuchi, Y.; Kawakami, S.; Hashida, M. Strategies for in Vivo Delivery of siRNAs Recent Progress BioDrugs 2010, 24, 195-205 10.2165/11534450-000000000-00000
202. Singha, K.; Namgung, R.; Kim, W. J. Polymers in Small-Interfering RNA Delivery Nucleic Acid Ther. 2011, 21, 133-147 10.1089/nat.2011.0293
203. Li, S. D.; Huang, L. Nanoparticles Evading the Reticuloendothelial System: Role of the Supported Bilayer Biochim. Biophys. Acta, Biomembr. 2009, 1788, 2259-2266 10.1016/j.bbamem.2009.06.022
204. Heyes, J.; Palmer, L.; Bremner, K.; MacLachlan, I. Cationic Lipid Saturation Influences Intracellular Delivery of Encapsulated Nucleic Acids J. Controlled Release 2005, 107, 276-287 10.1016/j.jconrel.2005.06.014
205. Meade, B. R.; Dowdy, S. F. Exogenous siRNA Delivery Using Peptide Transduction Domains/Cell Penetrating Peptides Adv. Drug Delivery Rev. 2007, 59, 134-140 10.1016/j.addr.2007.03.004
206. Tabet, F.; Vickers, K. C.; Torres, L. F. C.; Wiese, C. B.; Shoucri, B. M.; Lambert, G.; Catherinet, C.; Prado-Lourenco, L.; Levin, M. G.; Thacker, S.; Sethupathy, P.; Barter, P. J.; Remaley, A. T.; Rye, K. A. HDL-Transferred MicroRNA-223 Regulates ICAM-1 Expression in Endothelial Cells Nat. Commun. 2014, 5, 3292 10.1038/ncomms4292
207. Soutschek, J.; Akinc, A.; Bramlage, B.; Charisse, K.; Constien, R.; Donoghue, M.; Elbashir, S.; Geick, A.; Hadwiger, P.; Harborth, J.; John, M.; Kesavan, V.; Lavine, G.; Pandey, R. K.; Racie, T.; Rajeev, K. G.; Rohl, I.; Toudjarska, I.; Wang, G.; Wuschko, S. et al. Therapeutic Silencing of an Endogenous Gene by Systemic Administration of Modified siRNAs Nature 2004, 432, 173-178 10.1038/nature03121
208. Brown, M. S.; Goldstein, J. L. The Receptor Model for Transport of Cholesterol in Plasma Ann. N. Y. Acad. Sci. 1985, 454, 178-182 10.1111/j.1749-6632.1985.tb11856.x
209. Lin, Q. Y.; Chen, J.; Jin, H. L.; Ng, K. K.; Yang, M.; Cao, W. G.; Ding, L. L.; Zhang, Z. H.; Zheng, G. Efficient Systemic Delivery of siRNA by Using High-Density Lipoprotein-Mimicking Peptide Lipid Nanoparticles Nanomedicine 2012, 7, 1813-1825 10.2217/nnm.12.73
210. Ding, Y.; Wang, W.; Feng, M. Q.; Wang, Y.; Zhou, J. P.; Ding, X. F.; Zhou, X.; Liu, C. Y.; Wang, R. N.; Zhang, Q. A Biomimetic Nanovector-Mediated Targeted Cholesterol-Conjugated siRNA Delivery for Tumor Gene Therapy Biomaterials 2012, 33, 8893-8905 10.1016/j.biomaterials.2012.08.057
211. Glickson, J. D.; Lund-Katz, S.; Zhou, R.; Choi, H.; Chen, I. W.; Li, H.; Corbin, I.; Popov, A. V.; Cao, W. G.; Song, L. P.; Qi, C. Z.; Marotta, D.; Nelson, D. S.; Chen, J.; Chance, B.; Zheng, G. Lipoprotein Nanoplatform for Targeted Delivery of Diagnostic and Therapeutic Agents Molecular Imaging 2008, 7, 101-110
212. Frias, J. C.; Williams, K. J.; Fisher, E. A.; Fayad, Z. A. Recombinant HDL-Like Nanoparticles: A Specific Contrast Agent for MRI of Atherosclerotic Plaques J. Am. Chem. Soc. 2004, 126, 16316-16317 10.1021/ja044911a
213. Skajaa, T.; Cormode, D. P.; Jarzyna, P. A.; Delshad, A.; Blachford, C.; Barazza, A.; Fisher, E. A.; Gordon, R. E.; Fayad, Z. A.; Mulder, W. J. M. The Biological Properties of Iron Oxide Core High-Density Lipoprotein in Experimental Atherosclerosis Biomaterials 2011, 32, 206-213 10.1016/j.biomaterials.2010.08.078
214. Cao, W. G.; Ng, K. K.; Corbin, I.; Zhang, Z. H.; Ding, L. L.; Chen, J.; Zheng, G. Synthesis and Evaluation of a Stable Bacteriochlorophyll-Analog and Its Incorporation into High-Density Lipoprotein Nanoparticles for Tumor Imaging Bioconjugate Chem. 2009, 20, 2023-2031 10.1021/bc900404y
215. Lin, Q. Y.; Chen, J.; Ng, K. K.; Cao, W. G.; Zhang, Z. H.; Zheng, G. Imaging the Cytosolic Drug Delivery Mechanism of HDL-Like Nanoparticles Pharm. Res. 2014, 31, 1438-1449 10.1007/s11095-013-1046-z
216. Redondo, S.; Martinez-Gonzalez, J.; Urraca, C.; Tejerina, T. Emerging Therapeutic Strategies to Enhance HDL Function Lipids Health Dis. 2011, 10, 175 10.1186/1476-511X-10-175
217. Lundqvist, M.; Stigler, J.; Elia, G.; Lynch, I.; Cedervall, T.; Dawson, K. A. Nanoparticle Size and Surface Properties Determine the Protein Corona with Possible Implications for Biological Impacts Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 14265-14270 10.1073/pnas.0805135105
218. Ichikawa, K.; Takeuchi, Y.; Yonezawa, S.; Hikita, T.; Kurohane, K.; Namba, Y.; Oku, N. Antiangiogenic Photodynamic Therapy (PDT) Using Visudyne Causes Effective Suppression of Tumor Growth Cancer Lett. 2004, 205, 39-48 10.1016/j.canlet.2003.10.001
219. Wang, H.; Eckel, R. H. What Are Lipoproteins Doing in the Brain? Trends Endocrinol. Metab. 2014, 25, 8-14 10.1016/j.tem.2013.10.003
220. Sochaj, A. M.; Swiderska, K. W.; Otlewski, J. Current Methods for the Synthesis of Homogeneous Antibody-Drug Conjugates Biotechnol. Adv. 2015, 33, 775-84 10.1016/j.biotechadv.2015.05.001
221. Morin, E. E.; Guo, L.; Schwendeman, A.; Li, X. HDL in Sepsis-Risk Factor and Therapeutic Approach Front. Pharmacol. 2015, 6, 9 10.3389/fphar.2015.00244
222. Subramanian, C.; Kuai, R.; Zhu, Q.; White, P.; Moon, J. J.; Schwendeman, A.; Cohen, M. S. Synthetic High-Density Lipoprotein Nanoparticles: A Novel Therapeutic Strategy for Adrenocortical Carcinomas Surgery 2016, 159, 284-95 10.1016/j.surg.2015.08.023
223. Song, Q. X.; Huang, M.; Yao, L.; Wang, X. L.; Gu, X.; Chen, J.; Chen, J.; Huang, J. L.; Hu, Q. Y.; Kang, T.; Rong, Z. X.; Qi, H.; Zheng, G.; Chen, H. Z.; Gao, X. L. Lipoprotein-Based Nanoparticles Rescue the Memory Loss of Mice with Alzheimer's Disease by Accelerating the Clearance of Amyloid-Beta ACS Nano 2014, 8, 2345-2359 10.1021/nn4058215
224. Huang, M.; Hu, M.; Song, Q.; Song, H.; Huang, J.; Gu, X.; Wang, X.; Chen, J.; Kang, T.; Feng, X.; Jiang, D.; Zheng, G.; Chen, H.; Gao, X. GM1-Modified Lipoprotein-like Nanoparticle: Multifunctional Nanoplatform for the Combination Therapy of Alzheimer's Disease ACS Nano 2015, 9, 10801-16 10.1021/acsnano.5b03124